alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › tauopathies

tauopathies

387 studies tagged tauopathies, dated 1987-01-01 to 2026-10-31. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. APH-1A and CDK5 Expression Correlates with Tau Hyperphosphorylation and Its Attenuation by Brahmi and Donep-M in STZ induced Alzheimer’s Disease Model 2026-10-31
  2. Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions 2026-10-30
  3. The Alzheimer's disease-associated rs28834970 variant in PTK2B impairs electrical activity and regulates Tau phosphorylation and APP processing in human neuronal cultures 2026-10-30

Studies

387 studies carry this tag.

Date range

1987 to 2026

Top journals

  • Acta neuropathologica 16
  • Alzheimer's & dementia : the journal of the Alzheimer's Association 12
  • bioRxiv 12
  • Molecular neurodegeneration 10
  • Research Square 10

173 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. The therapeutic landscape of tauopathies: challenges and prospects

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2023-10-06 Clinical trials

    Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau.

  2. LATE-NC in Alzheimer's disease: Molecular aspects and synergies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain pathology (Zurich, Switzerland) 2023-10-04 Brain tissue and pathology

    Alzheimer's disease (AD) is classically characterized by senile plaques and neurofibrillary tangles (NFTs).

  3. TDP-43 pathology is associated with increased tau burdens and seeding

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Molecular neurodegeneration 2023-09-30 Brain tissue and pathology

    We found that AD cases with comorbid LATE-NC, AD(LATE-NC+), have increased burdens of pretangles and/or NFTs as well as increased brain levels of p-tau199, compared to AD(LATE-NC-) cases and controls.

  4. Transcriptomic Analysis in the Hippocampus and Retina of Tg2576 AD Mice Reveals Defective Mitochondrial Oxidative Phosphorylation and Recovery by Tau 12A12mAb Treatment

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cells 2023-09-12 Drug development

    Increasing evidence implicates decreased energy metabolism and mitochondrial dysfunctions among the earliest pathogenic events of Alzheimer's disease (AD).

  5. Primary retinal tauopathy: A tauopathy with a distinct molecular pattern

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-08-24 Risk factors

    Retinal p-tau pathology showed a consistent pattern with four stages and a molecular composition distinct from that of cerebral tauopathies.

  6. Apolipoprotein E isoform does not influence trans-synaptic spread of tau pathology in a mouse model

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and neuroscience advances 2023-08-17 Genetics

    A key hallmark of Alzheimer's disease (AD) is the accumulation of hyperphosphorylated tau in neurofibrillary tangles.

  7. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Expert opinion on investigational drugs 2023-07-10 Drug development

    Tauopathies are clinicopathological entities with increased and pathological deposition in glia and/or neurons of hyperphosphorylated aggregates of the microtubule-binding protein tau.

  8. Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. FEBS open bio 2023-07-08 Biomarkers

    The deposition of highly phosphorylated and aggregated tau is a characteristic of tauopathies, including Alzheimer's disease.

  9. Cryo-EM Structures of Chronic Traumatic Encephalopathy Tau Filaments with PET Ligand Flortaucipir

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of molecular biology 2023-06-16 Brain scans and imaging

    Positron emission tomography (PET) imaging allows monitoring the progression of amyloid aggregation in the living brain. [18F]-Flortaucipir is the only approved PET tracer compound for the visualisation of tau aggregation.

  10. Cyclosporine A (CsA) prevents synaptic impairment caused by truncated tau by caspase-3

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecular and cellular neurosciences 2023-05-12 Disease mechanisms

    During Alzheimer's (AD), tau protein suffers from abnormal post-translational modifications, including cleaving by caspase-3.

  11. Big tau aggregation disrupts microtubule tyrosination and causes myocardial diastolic dysfunction: from discovery to therapy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. European heart journal 2023-05-01 Drug development

    A mouse model of tauopathy and human myocardial and brain tissue from patients with HF, AD, and controls was employed in this study.

  12. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Nature 2023-03-08 Brain scans and imaging

    Extracellular deposition of amyloid-β as neuritic plaques and intracellular accumulation of hyperphosphorylated, aggregated tau as neurofibrillary tangles are two of the characteristic hallmarks of Alzheimer's disease 1,2 .

  13. Passive immunization inhibits tau phosphorylation and improves recognition learning and memory in 3xTg-AD mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Experimental neurology 2023-01-27 Drug development

    Tau pathology is essential in the pathogenesis of Alzheimer's disease (AD) and related tauopathies.

  14. Tau-aggregation inhibitors derived from Streptomyces tendae MCCC 1A01534 protect HT22 cells against okadaic acid-induced damage

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of biological macromolecules 2023-01-06 Drug development

    Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized by tau aggregating into neurofibrillary tangles.

  15. Passive tau-based immunotherapy for tauopathies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Handbook of clinical neurology 2023 Drug development

    Tauopathies are heterogeneous clinicopathological entities characterized by abnormal neuronal and/or glial inclusions of the microtubule-binding protein tau.

  16. Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. The journal of prevention of Alzheimer's disease 2023 Clinical trials

    The primary outcome is change in plasma p-tau181 concentration between baseline and following 180 days of treatment, which will be compared between the active and placebo group.

  17. The Late Stage of Abnormal Aging: Dementia

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Advances in experimental medicine and biology 2023 Drug development

    With the growth of the aging population, more age-related diseases endanger the health of the elderly, and therefore more research attention has been put on Alzheimer's disease and dementia.

  18. Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022-11-23 Drug development

    Accumulation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau is a histopathological hallmark of Alzheimer's disease (AD) and related tauopathies.

  19. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International immunopharmacology 2022-11-18 Drug development

    Tubulin-associated unit (tau) has been associated with more than 25 neurological disorders-the so-called tauopathies.

  20. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Nature communications 2022-11-04 Treatments

    For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to better understand the pathophysiological cascade of Aβ- and tau-related processes.

  21. Dysfunctional microglia and tau pathology in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Reviews in the neurosciences 2022-10-28 Inflammation and the immune system

    Extensive human studies and animal models show that chronic immune system stimulation involving microglia, inflammasome, complement activation, synthesis of cytokines, and reactive oxygen species exacerbates neurodegeneration in Alzheimer's disease (AD) and other tauopathies.

  22. TauLUM, an in vivo Drosophila sensor of tau multimerization, identifies neuroprotective interventions in tauopathy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cell reports methods 2022-09-09 Drug development

    Tau protein aggregates are a defining neuropathological feature of "tauopathies," a group of neurodegenerative disorders that include Alzheimer's disease.

  23. Active immunotherapy against pathogenic Cis pT231-tau suppresses neurodegeneration in traumatic brain injury mouse models

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neuropeptides 2022-09-03 Drug development

    Traumatic brain injury (TBI), characterized by acute neurological impairment, is associated with a higher incidence of neurodegenerative diseases, particularly chronic traumatic encephalopathy (CTE), Alzheimer's disease (AD), and Parkinson's disease (PD), whose hallmarks include hyperphosphorylated tau protein.

  24. Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neural regeneration research 2022-08-01 Drug development

    Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million dementia cases worldwide in 2018.

  25. Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neuron 2022-07-25 Genetics

    Tau aggregation in neurofibrillary tangles (NFTs) is closely associated with neurodegeneration and cognitive decline in Alzheimer's disease (AD).

  26. Inhibition of Microtubule Affinity Regulating Kinase 4 by Metformin: Exploring the Neuroprotective Potential of Antidiabetic Drug through Spectroscopic and Computational Approaches

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecules (Basel, Switzerland) 2022-07-21 Drug development

    Microtubule affinity regulating kinase 4 (MARK4) regulates the mechanism of microtubules by its ability to phosphorylate the microtubule-associated proteins (MAP's).

  27. Donepezil ameliorates Aβ pathology but not tau pathology in 5xFAD mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecular brain 2022-07-18 Treatments

    The cholinesterase inhibitor donepezil is used to improve Aβ pathology and cognitive function in patients with Alzheimer's disease (AD).

  28. An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. PloS one 2022-06-02 Drug development

    Tau protein is a key target of interest in developing therapeutics for neurodegenerative diseases.

  29. Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmaceutics 2022-05-24 Treatments

    Alzheimer's disease (AD) is the most common cause of dementia.

  30. Impact of APOE genotype on prion-type propagation of tauopathy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Acta neuropathologica communications 2022-04-19 Genetics

    Apolipoprotein (APOE) is a major risk factor of Alzheimer's disease (AD), with the E2, E3 and E4 isoforms differentially regulating the burden of AD-associated neuropathologies, such as amyloid β and tau.

  31. Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Nature communications 2022-04-12 Genetics

    Activation of microglia is a prominent pathological feature in tauopathies, including Alzheimer's disease.

  32. Overview of tau PET molecular imaging

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current opinion in neurology 2022-04-01 Brain scans and imaging

    This article reviews tau PET imaging with an emphasis on first-generation and second-generation tau radiotracers and their application in neurodegenerative disorders, including Alzheimer's disease and non-Alzheimer's disease tauopathies.

  33. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Translational neurodegeneration 2022-03-18 Treatments

    Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly worldwide.

  34. Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. European journal of nuclear medicine and molecular imaging 2022-02-07 Drug development

    PBB5 showed specific binding to recombinant K18 tau fibrils by fluorescence assay, to post-mortem Alzheimer's disease brain tissue homogenate by competitive binding against [11C]PBB3 and to tau deposits (AT-8 positive) in post-mortem corticobasal degeneration and progressive supranuclear palsy brains.

  35. A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Patterns (New York, N.Y.) 2022-01-26 Drug development

    The high number of failed pre-clinical and clinical studies for compounds targeting Alzheimer disease (AD) has demonstrated that there is a need to reassess existing strategies.

  36. Magnetic Resonance Imaging in Tauopathy Animal Models

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in aging neuroscience 2022-01-25 Brain scans and imaging

    The microtubule-associated protein tau plays an important role in tauopathic diseases such as Alzheimer's disease and primary tauopathies such as progressive supranuclear palsy and corticobasal degeneration.

  37. Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Chemical Society reviews 2022-01-24 Drug development

    Converging evidence continues to point towards Tau aggregation and pathology formation as central events in the pathogenesis of Alzheimer's disease and other Tauopathies.

  38. Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Acta neuropathologica communications 2022-01-06 Biomarkers

    Recent studies highlight phosphorylated tau (p-tau) at threonine tau 217 (p-tau217) as a new promising plasma biomarker for pathological changes implicated in Alzheimer's disease (AD), but the specific brain pathological events related to the alteration in p-tau217 plasma levels are still largely unknown.

  39. Long-Term Depression-Inducing Low Frequency Stimulation Enhances p-Tau181 and p-Tau217 in an Age-Dependent Manner in Live Rats

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Biomarkers

    We found that LFS enhanced p-Tau181 and p-Tau217 in an age-dependent manner in the hippocampus of live rats.

  40. Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurobiology of aging 2021-12-07 Brain scans and imaging

    Abnormally phosphorylated tau, an indicator of Alzheimer's disease, accumulates in the first decades of life in the locus coeruleus (LC), the brain's main noradrenaline supply.

  41. Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Bioorganic & medicinal chemistry 2021-11-20 Brain scans and imaging

    Tau aggregates represent a critical pathology in Alzheimer's disease (AD) and other forms of dementia.

  42. The role of pathological tau in synaptic dysfunction in Alzheimer's diseases

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Translational neurodegeneration 2021-11-10 Disease mechanisms

    Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline, accompanied by amyloid-β (Aβ) overload and hyperphosphorylated tau accumulation in the brain.

  43. Truncating tau reveals different pathophysiological actions of oligomers in single neurons

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Communications biology 2021-11-04 Drug development

    Tau protein is involved in maintaining neuronal structure.

  44. In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Science advances 2021-10-29 Brain scans and imaging

    Both the replication of protein aggregates and their spreading throughout the brain are implicated in the progression of Alzheimer’s disease (AD).

  45. Synaptic tau: A pathological or physiological phenomenon?

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Acta neuropathologica communications 2021-09-09 Disease mechanisms

    In this review, we discuss the synaptic aspects of Tau pathology occurring during Alzheimer's disease (AD) and how this may relate to memory impairment, a major hallmark of AD.

  46. Pretreatment with metformin prevents microcystin-LR-induced tau hyperphosphorylation via mTOR-dependent PP2A and GSK-3β activation

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Environmental toxicology 2021-08-25 Drug development

    Microcystin-leucine-arginine (MC-LR) is a toxin secreted by freshwater cyanobacteria that is considered a potential environmental risk factor for Alzheimer's disease (AD).

  47. Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain communications 2021-08-24 Brain scans and imaging

    To assess the ability of [18F]PI-2620 to detect regional tau burden in non-Alzheimer's disease tauopathies compared with Alzheimer's disease, patients with progressive supranuclear palsy (n = 3), corticobasal syndrome (n = 2), corticobasal degeneration (n = 1) or Alzheimer's disease (n = 8), and healthy controls (n = 7) were recruited.

  48. Cellular and pathological heterogeneity of primary tauopathies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Molecular neurodegeneration 2021-08-23 Genetics

    Microtubule-associated protein tau is abnormally aggregated in neuronal and glial cells in a range of neurodegenerative diseases that are collectively referred to as tauopathies.

  49. Autophagy and Tau Protein

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2021-07-12 Drug development

    Neurofibrillary tangles, which consist of highly phosphorylated tau protein, and senile plaques (SPs) are pathological hallmarks of Alzheimer's disease (AD).

  50. Current Status of Clinical Trials on Tau Immunotherapies

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Drugs 2021-06-08 Drug development

    Tau immunotherapies have advanced from proof-of-concept studies to over a dozen clinical trials for Alzheimer's disease (AD) and other tauopathies.

From across this tag

8 of the 387 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.

All topic tags with their study counts